Compare Stocks: NEUE, AIRS, XGN, and LFMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIRS AirSculpt Technologies	$2.13 -10.5%	$3.58	$1.51 ▼ $12.00	$171.59M	2.25	840,394 shs	1.11 million shs
LFMD LifeMD	$3.40 -1.2%	$3.61	$2.56 ▼ $7.32	$165.81M	2.04	694,325 shs	1.01 million shs
NEUE NeueHealth	$6.75	$6.75	$6.25 ▼ $6.99	$60.94M	0.59	6,683 shs	N/A
XGN Exagen	$7.49 +1.9%	$6.16	$2.59 ▼ $12.23	$178.06M	2.1	253,015 shs	221,718 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIRS AirSculpt Technologies	-10.50%	-21.11%	-37.90%	-55.72%	-64.08%
LFMD LifeMD	-1.16%	+10.03%	-1.45%	-30.75%	-41.68%
NEUE NeueHealth	0.00%	0.00%	0.00%	0.00%	+0.04%
XGN Exagen	+1.90%	+2.60%	+12.46%	+76.24%	-19.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIRS AirSculpt Technologies	$2.13 -10.5%	$3.58	$1.51 ▼ $12.00	$171.59M	2.25	840,394 shs	1.11 million shs
LFMD LifeMD	$3.40 -1.2%	$3.61	$2.56 ▼ $7.32	$165.81M	2.04	694,325 shs	1.01 million shs
NEUE NeueHealth	$6.75	$6.75	$6.25 ▼ $6.99	$60.94M	0.59	6,683 shs	N/A
XGN Exagen	$7.49 +1.9%	$6.16	$2.59 ▼ $12.23	$178.06M	2.1	253,015 shs	221,718 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIRS AirSculpt Technologies	-10.50%	-21.11%	-37.90%	-55.72%	-64.08%
LFMD LifeMD	-1.16%	+10.03%	-1.45%	-30.75%	-41.68%
NEUE NeueHealth	0.00%	0.00%	0.00%	0.00%	+0.04%
XGN Exagen	+1.90%	+2.60%	+12.46%	+76.24%	-19.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIRS AirSculpt Technologies	1.50	Reduce	$4.50	111.27% Upside
LFMD LifeMD	2.70	Moderate Buy	$7.57	122.69% Upside
NEUE NeueHealth	1.00	Sell	N/A	N/A
XGN Exagen	2.89	Moderate Buy	$9.63	28.50% Upside

Current Analyst Ratings Breakdown

Latest NEUE, AIRS, XGN, and LFMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	LFMD LifeMD	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
9/11/2026	XGN Exagen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/17/2026	LFMD LifeMD	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	XGN Exagen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	LFMD LifeMD	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$5.00
8/7/2026	LFMD LifeMD	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00 ➝ $9.00
8/6/2026	LFMD LifeMD	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
8/6/2026	LFMD LifeMD	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/6/2026	LFMD LifeMD	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00 ➝ $8.00
8/6/2026	LFMD LifeMD	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00 ➝ $9.00
8/5/2026	XGN Exagen	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIRS AirSculpt Technologies	$151.82M	1.01	$0.02 per share	133.39	$1.40 per share	1.52
LFMD LifeMD	$194.05M	0.84	N/A	N/A	$0.48 per share	7.08
NEUE NeueHealth	$890.44M	0.07	N/A	N/A	($163.57) per share	-0.04
XGN Exagen	$66.57M	2.73	N/A	N/A	$0.77 per share	9.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIRS AirSculpt Technologies	-$11.67M	-$0.18	N/A	N/A	N/A	-7.79%	-5.83%	-2.88%	11/9/2026 (Estimated)
LFMD LifeMD	$14.35M	-$0.05	N/A	N/A	N/A	0.10%	-168.23%	-31.27%	11/11/2026 (Estimated)
NEUE NeueHealth	-$134.68M	-$15.97	N/A	N/A	N/A	-9.08%	N/A	-13.01%	N/A
XGN Exagen	-$19.95M	-$0.81	N/A	N/A	N/A	-26.61%	-104.46%	-28.93%	11/3/2026 (Estimated)

Latest NEUE, AIRS, XGN, and LFMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AIRS AirSculpt Technologies	$0.0150	$0.01	-$0.0050	-$0.02	$44.14 million	$42.90 million
8/5/2026	Q2 2026	LFMD LifeMD	-$0.1457	-$0.16	-$0.0143	-$0.16	$49.16 million	$47.28 million
8/4/2026	Q2 2026	XGN Exagen	-$0.1914	-$0.13	+$0.0614	-$0.13	$17.80 million	$19.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIRS AirSculpt Technologies	N/A	N/A	N/A	N/A	N/A
LFMD LifeMD	N/A	N/A	N/A	N/A	N/A
NEUE NeueHealth	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIRS AirSculpt Technologies	0.32	0.79	0.79
LFMD LifeMD	N/A	0.90	0.84
NEUE NeueHealth	N/A	0.70	0.70
XGN Exagen	1.96	3.18	3.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIRS AirSculpt Technologies	91.54%
LFMD LifeMD	35.52%
NEUE NeueHealth	63.88%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
AIRS AirSculpt Technologies	44.60%
LFMD LifeMD	17.22%
NEUE NeueHealth	63.30%
XGN Exagen	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIRS AirSculpt Technologies	363	72.10 million	39.94 million	Optionable
LFMD LifeMD	384	48.20 million	39.90 million	Optionable
NEUE NeueHealth	1,252	9.02 million	3.31 million	N/A
XGN Exagen	220	24.23 million	21.71 million	Optionable

NEUE, AIRS, XGN, and LFMD Headlines

Recent News About These Companies

Exagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Review

4 hours ago | defenseworld.netD

Exagen (NASDAQ:XGN) Coverage Initiated at B. Riley Financial

September 13 at 1:43 AM | americanbankingnews.com

Exagen (NASDAQ:XGN) Now Covered by B. Riley Financial

September 11, 2026 | marketbeat.com

BlackRock Inc. Purchases Shares of 142,625 Exagen Inc. $XGN

September 7, 2026 | marketbeat.com

Man Group plc Takes $778,000 Position in Exagen Inc. $XGN

September 4, 2026 | marketbeat.com

Flputnam Investment Management Co. Acquires New Position in Exagen Inc. $XGN

August 31, 2026 | marketbeat.com

Exagen Inc. (NASDAQ:XGN) Given Average Rating of "Moderate Buy" by Brokerages

August 27, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN

August 18, 2026 | marketbeat.com

Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN

August 18, 2026 | marketbeat.com

Exagen (XGN) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

Exagen: The Path To Profitability Just Became More Credible

August 5, 2026 | seekingalpha.com

Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability

August 4, 2026 | finance.yahoo.com

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Exagen Inc. Reports Second Quarter 2026 Financial Results

August 4, 2026 | markets.businessinsider.com

Exagen reports record second-quarter 2026 revenue and raises full-year guidance

August 4, 2026 | msn.com

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2026 | zacks.com

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

August 4, 2026 | quiverquant.comQ

Exagen reports record Q2 revenue of $19.9 million

August 4, 2026 | quiverquant.comQ

Exagen Inc. to Participate in Upcoming Investor Conference

July 28, 2026 | globenewswire.com

Exagen: A Small Diagnostics Company Approaching An Inflection Point

July 23, 2026 | seekingalpha.com

Exagen to Announce Second Quarter Financial Results on August 4, 2026

July 21, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NEUE, AIRS, XGN, and LFMD Company Descriptions

AirSculpt Technologies NASDAQ:AIRS

$2.13 -0.25 (-10.50%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.10 -0.03 (-1.41%)

As of 07:42 AM Eastern

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. The company's body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

LifeMD NASDAQ:LFMD

$3.40 -0.04 (-1.16%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$3.39 -0.01 (-0.26%)

As of 08:40 AM Eastern

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

NeueHealth NYSE:NEUE

NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida.

Exagen NASDAQ:XGN

$7.49 +0.14 (+1.90%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$7.50 +0.01 (+0.13%)

As of 09/15/2026 07:30 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NEUE, AIRS, XGN, and LFMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NEUE, AIRS, XGN, and LFMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NEUE, AIRS, XGN, and LFMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NEUE, AIRS, XGN, and LFMD Company Descriptions

AirSculpt Technologies NASDAQ:AIRS

LifeMD NASDAQ:LFMD

NeueHealth NYSE:NEUE

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NEUE, AIRS, XGN, and LFMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NEUE, AIRS, XGN, and LFMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NEUE, AIRS, XGN, and LFMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NEUE, AIRS, XGN, and LFMD Company Descriptions

AirSculpt Technologies NASDAQ:AIRS

LifeMD NASDAQ:LFMD

NeueHealth NYSE:NEUE

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools